| Name | LY2510924 acetate(1088715-84-7 free base) |
| Description | Ly2510924 acetate is an potent and selective CXCR4 antagonist. It prevents the binding of SDF-1 to CXCR4 with an IC50 of 0.079 nM. |
| In vitro | In human lymphoma U937 cells expressing endogenous CXCR4, LY2510924 acetate inhibited SDF-1-induced cell migration with IC50 value of 0.26 nmol/L and inhibited SDF-1/CXCR4-mediated intracellular signaling. LY2510924 acetate exhibited a concentration-dependent inhibition of SDF-1-stimulated phospho-ERK and phospho-Akt in tumor cells. |
| In vivo | LY2510924 acetate showed dose-dependent inhibition of tumor growth in human xenograft models developed with non-Hodgkin lymphoma, renal cell carcinoma, lung, and colon cancer cells that express functional CXCR4. In MDA-MB-231, a breast cancer metastatic model, LY2510924 acetate inhibited tumor metastasis by blocking migration/homing process of tumor cells to the lung and by inhibiting cell proliferation after tumor cell homing. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/ml (47.98 mM)
|
| Keywords | LY2510924 acetate(1088715847 free base) | LY2510924 acetate(1088715 84 7 free base) | LY2510924 acetate(1088715-84-7 free base) | LY-2510924 acetate(1088715-84-7 free base) |
| Inhibitors Related | Tannic acid | Nicotinamide N-oxide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
